Hasil Pencarian  ::  Simpan CSV :: Kembali

"The “always on-hand” pocket guide to the treatment of infectious diseases.- The most important antibiotics and antimycotics :Spectrum – dosage – side-effects- Numerous tables sorted by substances, pathogens, indications- Administration of antibiotics during pregnancy, renal and hepatic insufficiency, dialysis- Including statements on the cost of therapyNumerous tips and troubleshooting guides on topics such as :- Potential mistakes- Therapy failures- Perioperative antibiotic prophylaxisAdjusted to European standards :Up-to-date substances, authorizations, resistances and trade names."

"The first book was on "Theory and practice" of antibiotic stewardship in its broadest sense -the how to do it and the do's and don’ts. The second, on "Controlling resistance" was very much on the relationships between use and resistance and beginning to home in on the hospital as the main generator of resistance, but mainly looking at it from a disease/clinical perspective. The last 3 chapters on MRSA, ended where the 3rd book will take off. "Controlling HAI " will concentrate on specific MDR organisms highlighting their roles in the current pandemic of HAI and emphasizing that the big issue is not so much infection control but antibiotic control, in the same way that antibiotic over-reliance/ over-use has caused the problem in the first place. Up 'till now the emphasis for controlling MRSA, C diff and all the other MDROs has very much been on IC, which clearly isn't working. This book will gather all the evidence for the increasingly popular view that much more must be done in the area of antibiotic policies/ stewardship, especially when we are in danger of a "post antibiotic" era, due to a real shortage of new agents in the pipeline."

"Buku ini diharapkan dapat menyediakan sebuah pendekatan/cara baru bagi terapis untuk menghadapi pasien kronis, tema dan pola yang relatif lama"

"ABSTRAKPeranan farmasi klinik di era JKN telah berkembang yaitu melakukan evaluasifarmakoekonomi terutama pada penggunaan antibiotik pasien anak di PICU yangberisiko tinggi akan resistensi. Tujuan penelitian adalah untuk mengevaluasi peranserta farmasi klinik pada terapi antibiotik secara ekonomi di PICU RSCM periodeMei-Oktober 2014. Metode yang digunakan adalah analisis efektivitas biaya.terhadap lama rawat pasien pada kelompok pasien yang tidak mendapatkanrekomendasi periode Mei-Juli 2014 (NR) dibandingkan dengan kelompok pasienyang mendapat rekomendasi dari farmasi klinik periode Agustus-Oktober 2014(R). Hasil yang diperoleh dari 42 pasien kelompok NR dan 51 pasien kelompok Radalah total biaya pada kelompok NR sebesar Rp 427.805.134, sedangkankelompok R sebesar Rp 349.302.060. Total lama rawat pasien pada kelompok NRadalah 268 hari, sedangkan kelompok R adalah 228 hari. Rata-rata lama rawat perpasien kelompok NR yaitu 6,4 hari sedangkan kelompok R yaitu 4,5 hari.Persentase efektivitas pada kelompok NR adalah 15,36%, sedangkan kelompok R22,22%. Hasil ACER kelompok NR adalah Rp 1.591.537/hari, sedangkan ACERkelompok NR adalah Rp 1.522.013/hari. Hasil analisa sensitivitasnya adalahdominan karena biaya lebih kecil sedangkan efektivitasnya lebih besar. Olehkarena itu, dapat disimpulkan bahwa peran serta farmasi klinik dalam terapi dapatmenurunkan biaya dan lama rawat pasien di PICU RSCM.

---

ABSTRACTThe role of clinical pharmacy in National Health Insurance era to evaluate the useof antibiotics has been evolved, especially for children in PICU which at high riskfor resistance. The research objective was to evaluate the role of clinical pharmacyon antibiotic therapy in the PICU RSCM period from May to October 2014. Themethod used is cost-effectiveness analysis to length of stay between the group ofpatients who did not received recommendation of clinical pharmacy in the periodMay - July 2014 (NR) compared with the group of patients who received therecommendation of clinical pharmacy period from August to October 2014 (R).The results were obtained from 42 patients NR group and 51 patients in the Rgroup. The total direct medical costs in the NR group Rp 427.805.134 , while theR group Rp 349.302.060. Total length of hospital patients in the NR group was268 days, while the R group was 228 days. Average length of stay per patient inthe NR group was 6.4 days, while R group was 4.5 days. Percentage of effectivityfrom the NR group was 15,36%, while the group R was 22,22 %. ACER in NRgroup is Rp 1.591.537 per length of stay, whereas the R group is Rp 1.522.013per length of stay. The results of the sensitivity analysis is dominant because thecosts was less , while its effectiveness is greater. Thus, it can be concluded thatparticipation in the clinical pharm"

"ABSTRAKLatar belakang: Pneumonia komunitas merupakan penyakit yang sering terjadi dan berhubungan dengan angka kesakitan dan kematian yang tinggi. Perhimpunan Dokter Paru Indonesia (PDPI) mengeluarkan pedoman pemberian antibiotik penanganan pasien pneumonia komunitas di Indonesia untuk mengurangi angka kematian pasien pneumonia komunitas.Tujuan: untuk mengetahui angka kepatuhan penggunaan panduan antibiotik untuk pasien pneumonia komunitas yang di rawat inap berdasarkan panduan PDPI di RSUP Persahabatan serta pengaruhnya terhadap lama perawatan dan angka mortalitas pasien.Metode: Penelitian observasional kohort retrospektif di Rumah Sakit Umum Pusat Persahabatan. Data diambil dari data rekam medis pasien yang didiagnosis pneumonia komunitas, yang dirawat di ruang rawat inap Departemen Pulmonologi dan Ilmu Kedokteran Respirasi RSUP Persahabatan, periode Juli 2014 sampai dengan Juli 2016.Hasil: Sampel penelitian 107 subjek, dengan karateristik pasien laki-laki 70,1% dan perempuan 29,9%. Median usia 56 tahun dengan usia minimum 18 tahun dan usia maksimum 96 tahun. Angka kepatuhan dokter terhadap penggunaan antibiotik berdasarkan pedoman penatalaksanaan pneumonia PDPI pada pasien pneumonia komunitas yang dirawat inap di RSUP Persahabatan sebesar 70,1%. Angka mortalitas pasien pneumonia komunitas berhubungan secara bermakna dengan kesesuaian pemberian antibiotik dengan pedoman PDPI dan derajat risiko PSI dengan nilai OR berturut-turut 2,93 (95%IK1,23-6,94) dan OR 3.02 (95%IK 1.25-7.29). Kesimpulan: Angka kepatuhan penggunaan antibiotik angka kepatuhan penggunaan panduan antibiotik untuk pasien pneumonia komunitas berdasarkan panduan PDPI berhubungan dengan angka mortalitas pasien.

---

ABSTRACT<>br>Background: Community acquired pneumonia (CAP) is a common disease and is associated with high morbidity and mortality. Indonesian Society of Respirology has been recommended empiric antibiotic guidelines for patients with community-acquired pneumonia in 2014. These guidelines are designed to reduce the mortality rate of CAP patients. Objective: to determine the compliance rate of antibiotic guidance for inpatient community pneumonia patients based on PDPI antibiotic guidelines in Persahabatan Hospital and its effect on the length of stay and mortality rate CAP patients. Method: This is a retrospective cohort observational study inPersahabatan Hospital. Data were collected from medical records of patients diagnosed with CAP, who were admitted to the Department of Pulmonology and Respiratory Medicine during July 2014 to July 2016. Results: The sample was 107 subjects. Proportion male and female were 70.1% and 29.9%. The median age was 56 years old with a minimum age was 18 years and a maximum age was 96 years. Doctors' compliance rates on PDPI's guidelines for the management CAP patients was 70.1%. The mortality rate of CAP patients was significantly associated with the national guidelines-concordant empiric antibiotic therapy and the class risk of PSI with OR 2.93 (95% IK1,23-6,94) and OR 3.02 (95% IK 1.25-7.29) reversely. "

"Upaya untuk memaksimalkan penggunaan antibiotik yang rasional merupakan salah satu tanggung jawab penting dari pelayanan farmasi. Penggunaan obat dikatakan rasional jika obat yang digunakan sesuai indikasi, kondisi pasien dan pemilihan obat yang tepat terkait jenis, sediaan, dosis, rute, waktu dan lama pemberian, mempertimbangkan manfaat dan resiko dari obat yang digunakan. Penggunaan antibiotik yang tidak tepat dapat menyebabkan pengobatan lebih mahal, efek samping lebih toksik, meluasnya resistensi dan timbulnya kejadian superinfeksi yang sulit diobati. Setelah melakukan pemantauan terapi obat pada pasien di ruang ICU RSUP Fatmawati, kesimpulan yang didapat: Pengobatan yang diterima oleh Nn. TRA sudah sesuai dengan indikasi penyakit, yaitu abses submandibularis, dengan frekuensi pengobatan dan dosis antibiotik juga dinilai sudah tepat. Pada Ny. AAH, didapatkan adanya obat yang tidak sesuai indikasi, yaitu tigecycline dan penggunaan meropenem serta levofloxacin juga tidak tepat dosis dan tidak tepat frekuensi pemakaian. Sepanjang penggunaan tigecycline, kondisi pasien justru memburuk hingga kemudian dinyatakan meninggal pada tanggal 11 April 2022 akibat gagal ventilasi dan sepsis pneumonia. Penggunaan tigecycline kemungkinan tidak efektif. Perhitungan DDD/100 patient-days, meropenem memiliki nilai DDD tertinggi,  kemudian disusul oleh amikasin, levofloxacin, metronidazole, dan tigecycline secara berurutan. Pada perhitungan DU 90 %, meropenem, amikacin, dan levofloxacin termasuk dalam segmen tersebut. Antibiotik yang memiliki nilai DDD/100 patient-days yang tinggi dan termasuk dalam segmen 90 % perlu diawasi penggunaannya dengan baik karena penggunaan yang tinggi dapat meningkatkan resiko terjadinya resisten antibiotik.

---

Efforts to maximize the rational use of antibiotics is one of the important responsibilities of pharmaceutical services. The use of drugs is said to be rational if the drugs used are according to the indications, the patient's condition and the selection of the right drug regarding type, preparation, dose, route, time and duration of administration, considering the benefits and risks of the drug used. Inappropriate use of antibiotics can cause more expensive treatment, more toxic side effects, widespread resistance and the emergence of superinfections that are difficult to treat. After monitoring drug therapy on patients in the ICU at Fatmawati Hospital, the conclusion was obtained: The treatment received by Ms. TRA is in accordance with the indications of the disease, namely submandibular abscess, with the frequency of treatment and dosage of antibiotics also considered to be appropriate. To Mrs. AAH, it was found that there were drugs that were not according to indications, namely tigecycline and the use of meropenem and levofloxacin, which also included incorrect doses and incorrect frequency of use. Throughout the use of tigecycline, the patient's condition worsened until he was declared dead on April 11 2022 due to ventilation failure and pneumonia sepsis. The use of tigecycline may not be effective. Calculating DDD/100 patient-days, meropenem has the highest DDD value, followed by amikacin, levofloxacin, metronidazole, and tigecycline in sequence. In the 90% DU calculation, meropenem, amikacin, and levofloxacin are included in this segment. Antibiotics that have a high DDD/100 patient-days value and are included in the 90% segment need to be monitored carefully because high use can increase the risk of antibiotic resistance."